Topic: Sanofi-Aventis SA

Stenting for Carotid Stenosis Unsafe for Older Adults

Modern Medicine - 7 hours ago
Stenting for treatment of carotid stenosis should be avoided in patients 70 years of age or older, but the approach appears to be as safe as...

Suitor won’t raise bid for Genzyme

Boston Globe - 19 hours ago
Sanofi-Aventis SA is sticking to its original offer of $69 per share to buy Genzyme Corp., a Sanofi spokesman said yesterday.. . That's despite...

Sanofi-Aventis sticking to first offer for Genzyme

AP Features - yesterday
French drugmaker Sanofi-Aventis SA is sticking to its original offer of $69 per share to buy U.S. biotech company Genzyme Corp., a Sanofi spokesman said Thursday.That's despite rumors Paris-based Sanofi has upped its offer by $2 a share, two ...

Sanofi Ups The Pressure On Genzyme (SNY, GENZ, SHPGY, PLX, ISIS)

Investopedia - yesterday
It is not exactly a hostile bid, but French drug company Sanofi-aventis (NYSE:SNY) has certainly stepped up its efforts to acquire American rare...

Sanofi ups its bid to buy Genzyme

EuroNews - yesterday
French pharmaceuticals group Sanofi-Aventis has made a new bid to buy US biotech company Genzyme. Sanofi is offering 71 dollars a share, or just...

Sanofi sticks to $69 per share Genzyme offer

Reuters US Online Report Business News - yesterday
PARIS (Reuters) - French drugmaker Sanofi-Aventis poured cold water on reports it had raised its offer for Genzyme , saying it was sticking to its bid of $18.5 billion, or $69 per share."There is one offer, at $69 a share," spokeman Jean-Marc ...

Sanofi Sticks to $69 Per Share Genzyme Offer

New York Times - yesterday
French drugmaker Sanofi-Aventis poured cold water on reports it had raised its offer for Genzyme, saying it was sticking to its bid of $18.5 ...

Sanofi Pitched $71 Offer to Genzyme: Report

ABC News - 2 days ago
Sanofi-Aventis SA pitched a new offer to acquire U.S. biotechnology company Genzyme Corp for $71 a share in exchange for the opportunity to conduct ...

Sanofi C.E.O. Talks to Genzyme Investors

DealBook - 2 days ago
Sanofi-Aventis's chief executive Chris Viehbacher took his case for a takeover directly to Genzyme's investors in meetings in New York Tuesday...

Hostile Bid in the Works for Genzyme Corp (NASDAQ: GENZ), Citigroup, Inc (NYSE: C) Says

American Banking News - 38 days ago
Citigroup, Inc (NYSE: C) analysts said in a research note that Sanofi-Aventis SA may begin a hostile bid for Genzyme Corp (NASDAQ: GENZ) if the...